HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
Operates as a pharmaceutical company that specializes in acute care hospital products. Its first acute care hospital product, Angiomax (bivalirudin), is a direct thrombin inhibitor used as an anticoagulant in patients undergoing coronary angioplasty.
Market Cap | 6.73 Billion | Shares Outstanding | 79.933 Million | Avg 30-day Volume | |||
P/E Ratio | Dividend Yield | EPS | -3.107 | ||||
Price/Sales | Debt to Equity | EBITDA | |||||
Price to Book Value | 0.0 | Forward PE | Enterprise Value | ||||
Total Cash | Current Debt | Gross Profit | |||||
BETA | 52-week High/Low | 84.3 / 16.69 | Next Earnings Date | Price to Cash FLow (P/CF) | |||
Data provided by IEX Cloud |
Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
No data found for this quarter. | ||||||
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MEANWELL CLIVE CHIEF INNOVATION OFFICER |
|
0 | 2020-01-06 | 0 |
RODIN STEPHEN M EVP AND GENERAL COUNSEL |
|
0 | 2020-01-06 | 0 |
|
0 | 2020-01-06 | 0 | |
|
0 | 2020-01-06 | 0 | |
|
0 | 2020-01-06 | 0 | |
|
0 | 2020-01-06 | 0 | |
VISIOLI CHRISTOPHER CHIEF FINANCIAL OFFICER |
|
0 | 2020-01-06 | 0 |
TIMNEY MARK CHIEF EXECUTIVE OFFICER |
|
0 | 2020-01-06 | 0 |
WIJNGAARD PETER CHIEF DEVELOPMENT OFFICER |
|
0 | 2020-01-06 | 0 |
|
0 | 2019-09-26 | 0 | |
COX CHRISTOPHER T EVP & CHIEF CORP. DEV. OFFICER |
|
392,942 | 2019-03-04 | 0 |
ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN |
|
2,076,686 | 2018-05-31 | 0 |
|
53,133 | 2018-05-25 | 0 | |
|
138,493 | 2018-05-10 | 0 | |
|
60,633 | 2018-03-22 | 0 | |
|
53,133 | 2018-03-21 | 0 | |
O'CONNOR WILLIAM BERNARD CHIEF FINANCIAL OFFICER |
|
21,882 | 2018-03-02 | 0 |
FRAZIER JEFF EVP, CHIEF HUMAN STRATEGY |
|
34,350 | 2018-03-02 | 0 |
|
163,431 | 2017-11-09 | 0 | |
|
26,784 | 2017-05-25 | 0 | |
KINGSLEY STUART A PRESIDENT AND COO |
|
11,386 | 2017-03-01 | 0 |
|
31,146 | 2016-05-26 | 0 | |
SBLENDORIO GLENN PRESIDENT & CFO |
|
99,805 | 2015-09-03 | 0 |
FURSE BRENT EVP, CHIEF CUSTOMER OFFICER |
|
41,044 | 2014-08-29 | 0 |
KUSIAK VICTORIA EVP, CHIEF INTEGRITY OFFICER |
|
3,519 | 2014-03-03 | 0 |
HEIMAN CORNELIS EVP, CHIEF INNOVATION OFFICER |
|
11,457 | 2014-03-03 | 0 |
ANTINORI PAUL MICHAEL SR. VP & GENERAL COUNSEL |
|
No longer subject to file | 2014-02-25 | 0 |
ROHRBACKER LESLIE C VP, CHIEF HUMAN STRATEGY OFFIC |
|
13,628 | 2012-02-21 | 0 |
|
No longer subject to file | 2011-04-04 | 0 | |
JOHNSON T SCOTT |
|
No longer subject to file | 2009-07-21 | 0 |
WATSON PACICCO KELLI SENIOR VICE PRESIDENT |
|
2,211 | 2009-02-20 | 0 |
KELLEY JOHN P PRESIDENT AND COO |
|
55,615 | 2009-02-20 | 0 |
NEWBERRY CATHARINE S SENIOR VICE PRESIDENT |
|
No longer subject to file | 2009-01-26 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund | MDCO | -1233.0 shares, $-104731.02 | 2019-12-31 | N-PORT |
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund | MDCO | -8687.0 shares, $-434350.0 | 2019-09-30 | N-PORT |
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund | MDCO | -26680.0 shares, $-1334000.0 | 2019-09-30 | N-PORT |
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | MDCO | -257.0 shares, $-12850.0 | 2019-09-30 | N-PORT |